• Weleda is less well since the delisting of homeopathy in France.

  • The Swiss group has announced its desire to cut 127 jobs in France, especially in Huningue in Alsace.

  • “We didn't expect it at all, we were always told that cosmetics could compensate for losses.

    An accountant mandated by the CSE told us that the group had a very good woolen stocking.

    It is still the employees who will toast, ”laments Laurence Saturni, CFTC delegate.

Bad news for employment.

Faced with difficulties since the delisting of homeopathy by Social Security, the Swiss pharmaceutical group Weleda has announced its desire to cut 127 jobs in France.

This plan should mainly affect the factory in Huningue, in the Haut-Rhin.

"It is essential today to rethink our operational model in order to stem our losses and thus be able to continue to be a pioneering and innovative company in the market of health, care and natural and organic beauty", indicated in a press release published Monday, Ludovic Rassat, chairman of the board of Weleda France.

"It's still the employees who will drink"

According to the regional daily Les Derniers Nouvelles d'Alsace, the turnover of Weleda France, which amounted to 95 million euros in 2019, has fallen by 36% since this date, plagued by the end of reimbursement of products. effective in January 2021. The group plans the “cessation of production activities on the Huningue site”, where a hundred jobs are at stake out of the 325 counted by the trade unions.

Faced with the management's project which notes an "acceleration" of "economic difficulties", Laurence Saturni, CFTC delegate, denounced "a crushing blow".

“We didn't expect it at all, we were always told that cosmetics could compensate for losses.

An accountant mandated by the CSE told us that the group had a very good woolen stocking.

It is still the employees who will drink, ”she laments.

The Parisian boutique will close its doors

"Our sales space in Paris, avenue Franklin Roosevelt, will close while hundreds of thousands of euros have been invested there, the fleet of around twenty medical visitors will be eliminated", explains Ms. Saturni, attached to the Alsatian site. of the Swiss-based multinational which employs 2,500 people worldwide.

The first departures from Huningue, where the company has been established since 1924, should take place in January.

Pharmaceutical production will be repatriated to Germany, to the Schwäbisch Gmünd site, located about fifty kilometers east of Stuttgart, according to Ms Saturni.

In its French market, the group has indicated that it now wants to develop its self-medication activity, after having launched in 2018 in the food supplements segment.

Economy

Strasbourg: Adidas is leaving... Is Strasbourg paying for a lack of attractiveness?

Planet

Alsace: With a record number of wild animals in distress, the LPO calls for help

  • Economy

  • Strasbourg

  • Great East

  • Pharmaceutical industry

  • Use